<DOC>
	<DOC>NCT02125305</DOC>
	<brief_summary>This study aims to investigate the pharmacokinetics/pharmacodynamics metformin IR after oral administration in healthy elderly male volunteers.</brief_summary>
	<brief_title>Clinical Study to Investigate the Pharmacokinetics and Pharmacodynamics of Metformin in the Elderly</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<criteria>Males aged 6585 years with a body mass index (BMI) of 1828 kg/m2 Good health based on complete medical history, physical examinations, vital signs, electrocardiography (ECG), and clinical laboratory evaluations including hematology (blood cell count, hemoglobin, and platelet count), liver function test (aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin), serum creatinine, blood glucose and urinalysis If they had clinically relevant disorders Past history of diabetes or clinical findings to suspect diabetes Abnormal clinical laboratory values (i.e., platelets ≤ 75,000/mm3, hemoglobin ≤ 9 g/dL, neutrophils absolute ≤ 1000/mm3, fasting glucose &gt; 126mg/dL, creatinine ≥ 1.5 mg/dL, or AST, ALT &gt; 3 × upper limit of normal)</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Metformin</keyword>
	<keyword>Pharmacokinetics/ Pharmacodynamics</keyword>
</DOC>